Q4 2018 Earnings Estimate for Tabula Rasa HealthCare Inc Issued By Oppenheimer (TRHC)

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) – Equities researchers at Oppenheimer decreased their Q4 2018 earnings per share (EPS) estimates for shares of Tabula Rasa HealthCare in a report released on Tuesday, November 6th. Oppenheimer analyst M. Naidu now anticipates that the company will post earnings per share of $0.19 for the quarter, down from their previous estimate of $0.22. Oppenheimer has a “Outperform” rating and a $86.00 price target on the stock.

Other equities research analysts have also issued reports about the company. Citigroup raised their price objective on Tabula Rasa HealthCare to $100.00 and gave the company a “buy” rating in a research note on Thursday, October 11th. BidaskClub lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 15th. Zacks Investment Research raised Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $74.00 price objective for the company in a research note on Saturday, August 11th. Robert W. Baird reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Tabula Rasa HealthCare in a research note on Wednesday, August 8th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $99.00 price objective on shares of Tabula Rasa HealthCare in a research note on Tuesday. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Tabula Rasa HealthCare has a consensus rating of “Buy” and a consensus target price of $81.60.

NASDAQ:TRHC opened at $72.96 on Friday. The company has a market capitalization of $1.36 billion, a PE ratio of -1,824.00, a P/E/G ratio of 5.08 and a beta of 2.58. Tabula Rasa HealthCare has a 1 year low of $27.10 and a 1 year high of $91.16. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.36 and a quick ratio of 0.33.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.07. The business had revenue of $54.42 million during the quarter, compared to analyst estimates of $52.87 million. Tabula Rasa HealthCare had a positive return on equity of 7.53% and a negative net margin of 13.49%. The company’s revenue for the quarter was up 66.3% on a year-over-year basis. During the same period last year, the company earned $0.08 EPS.

In other news, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $85.98, for a total value of $687,840.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 48,000 shares of company stock worth $3,722,960. Company insiders own 14.00% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. American International Group Inc. raised its holdings in shares of Tabula Rasa HealthCare by 6.0% in the third quarter. American International Group Inc. now owns 13,664 shares of the company’s stock worth $1,109,000 after buying an additional 772 shares during the period. BlackRock Inc. raised its holdings in shares of Tabula Rasa HealthCare by 20.8% in the third quarter. BlackRock Inc. now owns 2,560,710 shares of the company’s stock worth $207,904,000 after buying an additional 441,203 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Tabula Rasa HealthCare by 20.8% in the third quarter. Bank of New York Mellon Corp now owns 258,613 shares of the company’s stock worth $20,996,000 after buying an additional 44,551 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Tabula Rasa HealthCare by 119.0% in the third quarter. Janus Henderson Group PLC now owns 10,674 shares of the company’s stock worth $867,000 after buying an additional 5,799 shares during the period. Finally, Artemis Investment Management LLP purchased a new stake in shares of Tabula Rasa HealthCare in the third quarter worth approximately $371,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Featured Story: Stock Symbols and CUSIP Explained

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply